Author: Gupta, Ajay; Kalantar-Zadeh, Kamyar; Reddy, Srinivasa T.
Title: Ramatroban as a Novel Immunotherapy for COVID-19 Cord-id: 0u2spkyx Document date: 2020_7_30
ID: 0u2spkyx
Snippet: SARS-CoV-2 virus suppresses host innate and adaptive immune responses, thereby allowing the virus to proliferate, and cause multiorgan failure, especially in the elderly. Respiratory viruses stimulate cyclooxygenase-2 (COX-2) to generate prostanoids including Prostaglandin D(2) (PGD(2)) and thromboxane A(2). Furthermore, PGD(2) concentrations in the airways increase with aging. PGD(2) action mediated via DP(2) receptors suppresses both innate and adaptive immune responses, by inhibiting interfer
Document: SARS-CoV-2 virus suppresses host innate and adaptive immune responses, thereby allowing the virus to proliferate, and cause multiorgan failure, especially in the elderly. Respiratory viruses stimulate cyclooxygenase-2 (COX-2) to generate prostanoids including Prostaglandin D(2) (PGD(2)) and thromboxane A(2). Furthermore, PGD(2) concentrations in the airways increase with aging. PGD(2) action mediated via DP(2) receptors suppresses both innate and adaptive immune responses, by inhibiting interferon-λ and stimulation of myeloid monocyte-derived suppressor cells respectively. PGD(2) and thromboxane A(2) actions via the TP receptors activate platelets leading to a prothrombotic state. Ramatroban, a small-molecule antagonist of DP(2) and TP receptors, reverses viremia-associated proinflammatory, immunosuppressive5 and prothrombotic processes which are similar to those induced by SARS-Cov-2. Ramatroban, used for the treatment of allergic rhinitis in Japan for the past 20 years has an excellent safety profile. Therefore, Ramatroban merits investigation as a novel immunotherapy for the treatment of COVID-19 disease.
Search related documents:
Co phrase search for related documents- active area and adaptive immune system: 1
- active area and lung airway: 1
- active area and lung injury: 1
- active area and lung tissue: 1
- acute lung injury and adaptive immune response: 1, 2, 3, 4, 5
- acute lung injury and adaptive immune system: 1, 2, 3
- acute lung injury and adhesion molecule: 1, 2, 3, 4, 5, 6, 7, 8
- acute lung injury and local production: 1
- acute lung injury and lung airway: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- acute lung injury and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute lung injury and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute lung injury induce and lung injury: 1, 2, 3, 4, 5, 6
- acute lung injury induce and lung tissue: 1, 2, 3, 4
- adaptive immune response and adhesion molecule: 1, 2, 3
- adaptive immune response and local production: 1
- adaptive immune response and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9
- adaptive immune response and lung tissue: 1, 2, 3, 4, 5, 6, 7
- adaptive immune system and lung injury: 1, 2, 3
- adaptive immune system and lung tissue: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date